| Tiffany Tam, PHARMD | |
|
1100 Fairview Ave N, Seattle, WA 98109-4433 | |
| (206) 667-5000 | |
| Not Available |
| Full Name | Tiffany Tam |
|---|---|
| Gender | Female |
| Speciality | Pharmacist - Oncology |
| Location | 1100 Fairview Ave N, Seattle, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003597949 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835X0200X | Pharmacist - Oncology | PH61085194 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tiffany Tam, PHARMD 2843 Sw Adams St Unit A, Seattle, WA 98126-2517 Ph: () - | Tiffany Tam, PHARMD 1100 Fairview Ave N, Seattle, WA 98109-4433 Ph: (206) 667-5000 |
News Archive
Children with a genetic disorder called 22q11.2 deletion syndrome, who frequently are believed to also have autism, often may be misidentified because the social impairments associated with their developmental delay may mimic the features of autism, a study by researchers with the UC Davis MIND Institute suggests.
An estimated 14−17% of hospitalized COVID-19 patients develop a severe form of the disease, requiring oxygen support and admission to the intensive care unit.
Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinson's disease psychosis (PDP), which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program.
Geert Cappelaere, UNICEF's representative in Yemen, said the country is facing humanitarian challenges and is "absolutely in dire need of humanitarian assistance," Reuters reports.
Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Dr. Richard Stone, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology Annual Meeting and Exposition in Orlando.
› Verified 6 days ago
Genia J Moncada, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 325 9th Ave, Mailstop 359912, Seattle, WA 98104 Phone: 206-731-3219 Fax: 206-731-6076 | |
Leonie A Neville, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-598-4874 | |
Evelyn Wong, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1100 9th Ave #ms A-call, Seattle, WA 98101 Phone: 206-223-6000 | |
Marcie G Hume, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1100 9th Ave, Ms C3-po, Seattle, WA 98101 Phone: 206-223-6877 | |
Kathryn Tamura, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1959 Ne Pacific St, Box 356015, Seattle, WA 98195 Phone: 206-598-6060 Fax: 206-598-6075 | |
Dr. Stacey Ng, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2201 E. Madison Street, Seattle, WA 98112 Phone: 206-494-1520 Fax: 206-494-1523 | |
Ashley Nicole Wilson, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 747 Broadway, Attn: Inpatient Pharmacy, Seattle, WA 98122 Phone: 206-215-6283 |